Abstract
Adenosine, a widely distributed modulator, regulates many physiological functions through specific cell membrane G-protein-coupled receptors classified as A1, A2A, A2B and A3. An intense medicinal chemistry effort made over the last 20 years has led to a variety of selective adenosine receptor agonists and antagonists. In particular, the pyrazolo-triazolo-pyrimidine nucleus has been strongly investigated in the last years by our group. All the modifications performed and a tentative of structure-activity-relationship is reported. In fact, the combination of different substitutions at the N7, N8 and N5 positions afford compounds which showed good affinity and selectivity for the different adenosine receptor subtypes. The data herein summarized, permit to speculate on the use of this nucleus as possible template for the adenosine receptor subtypes.
Keywords: pyrazolo-triazolo-pyrimidine, adenosine receptor, adenosine antagonist, adenosine receptor subtype
Current Pharmaceutical Design
Title: Pyrazolo-Triazolo-Pyrimidine Derivatives as Adenosine Receptor Antagonists: A Possible Template for Adenosine Receptor Subtypes?
Volume: 8 Issue: 26
Author(s): Pier Giovanni Baraldi, Barbara Cacciari, Pier Andrea Borea, Katia Varani, Giorgia Pastorin, Tatiana Da Ros, Mojgan Aghazadeh Tabrizi, Francesca Fruttarolo and Giampiero Spalluto
Affiliation:
Keywords: pyrazolo-triazolo-pyrimidine, adenosine receptor, adenosine antagonist, adenosine receptor subtype
Abstract: Adenosine, a widely distributed modulator, regulates many physiological functions through specific cell membrane G-protein-coupled receptors classified as A1, A2A, A2B and A3. An intense medicinal chemistry effort made over the last 20 years has led to a variety of selective adenosine receptor agonists and antagonists. In particular, the pyrazolo-triazolo-pyrimidine nucleus has been strongly investigated in the last years by our group. All the modifications performed and a tentative of structure-activity-relationship is reported. In fact, the combination of different substitutions at the N7, N8 and N5 positions afford compounds which showed good affinity and selectivity for the different adenosine receptor subtypes. The data herein summarized, permit to speculate on the use of this nucleus as possible template for the adenosine receptor subtypes.
Export Options
About this article
Cite this article as:
Baraldi Giovanni Pier, Cacciari Barbara, Borea Andrea Pier, Varani Katia, Pastorin Giorgia, Da Ros Tatiana, Tabrizi Aghazadeh Mojgan, Fruttarolo Francesca and Spalluto Giampiero, Pyrazolo-Triazolo-Pyrimidine Derivatives as Adenosine Receptor Antagonists: A Possible Template for Adenosine Receptor Subtypes?, Current Pharmaceutical Design 2002; 8 (26) . https://dx.doi.org/10.2174/1381612023392838
DOI https://dx.doi.org/10.2174/1381612023392838 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regular Physical Activity and Vascular Aging
Current Pharmaceutical Design Nutrigenomics and its Impact on Life Style Associated Metabolic Diseases
Current Genomics Fenoldopam in Cardiovascular Surgery: A Review
Vascular Disease Prevention (Discontinued) Downstream Processing of Bioactive Compounds from Milk and Whey
Current Biochemical Engineering (Discontinued) Treating and Preventing No Reflow in the Cardiac Catheterization Laboratory
Current Cardiology Reviews Neuroprotection by the α2-Adrenoceptor Agonist, Dexmedetomidine, in Experimental Stroke Models
Vascular Disease Prevention (Discontinued) Tolvaptan: A New Therapeutic Agent
Reviews on Recent Clinical Trials Advanced Therapies For End-Stage Heart Failure
Current Cardiology Reviews Rivastigmine for Refractory REM Behavior Disorder in Mild Cognitive Impairment
Current Alzheimer Research Endothelin-Converting Enzyme Inhibitors
Current Enzyme Inhibition Intravenous Immunoglobulin as a Potential Therapy for Refractory Urticaria - A Review
Inflammation & Allergy - Drug Targets (Discontinued) Cyclodextrin Based Nanosponges: A Multidimensional Drug Delivery System and its Biomedical Applications
Current Drug Delivery Does Daily Dialysis Improve Hypertension in Chronic Haemodialysis Patients?
Current Hypertension Reviews Pharmacovigilance and the Cardiovascular System: Two Sides to Every Story
Current Drug Safety Association of Viruses in the Development of Cardiovascular Diseases
Current Pharmaceutical Design Hypotensive Effects of the Triterpene Oleanolic Acid for Cardiovascular Prevention
Current Molecular Pharmacology Oral Health in Alzheimers Disease: A Review
Current Alzheimer Research The Role of Transcription Factors in the Formation of an Arrhythmogenic Substrate in Congestive Human Heart Failure
Current Medicinal Chemistry Studies on Novel Pyridine and 2-pyridone Derivatives of N-arylpiperazine as α-adrenoceptor Ligands
Medicinal Chemistry Editorial [Hot Topic: Inhibition of the Renin-Angiotensin-Aldosterone System: How to Obtain This (Executive Guest Editors: Aldo Pende and Fabrizio Montecucco )]
Current Pharmaceutical Design